| Not Yet Recruiting | Pacritinib With Aza for Upfront Myelodysplastic Syndrome NCT07387354 | Thomas Jefferson University | Phase 1 / Phase 2 |
| Recruiting | MT2025-35 Allogeneic Hematopoietic Stem Cell Transplantation Using Reduced Intensity Conditioning Treosulfan a NCT07493538 | Masonic Cancer Center, University of Minnesota | Phase 2 |
| Recruiting | Quality of Life-Guided Transfusion in Refractory MDS or AML NCT07328191 | Centre Hospitalier Universitaire de Nice | N/A |
| Recruiting | A Long Term Follow-up Study of TScan TCR-T Products NCT06976736 | TScan Therapeutics, Inc. | — |
| Not Yet Recruiting | QH101 Cell Therapy Relapsed/Refractory(R/R) Acute Myeloid Leukemia(AML) and Myelodysplastic Syndromes(MDS) NCT07131085 | Anhui Provincial Hospital | Phase 1 |
| Not Yet Recruiting | Reduced Intensity Conditioning for MDS NCT07085156 | Ruijin Hospital | Phase 2 |
| Recruiting | Prospective Evaluation of Ivosidenib Maintenance Following Allogeneic Stem Cell Transplantation in Patients Wi NCT06717958 | Technische Universität Dresden | Phase 2 |
| Recruiting | Safety of MT-401-OTS in Patients With Relapsed AML or MDS NCT06552416 | Marker Therapeutics, Inc. | Phase 1 |
| Recruiting | Molecular Genetics Guide the Maintenance Therapy After Allogeneic Hematopoietic Stem Cell Transplantation NCT06972641 | Ruijin Hospital | Phase 2 / Phase 3 |
| Recruiting | A Study of Oral Tetrahydrouridine-Decitabine in Relapsed or Refractory Myelodysplastic Syndromes (MDS) NCT07006025 | Treebough Therapies | Phase 1 |
| Recruiting | Replacing Bone Marrow Diagnostics With Peripheral Blood Analysis in Cytopenia Patients NCT07081087 | Weizmann Institute of Science | — |
| Recruiting | Comparison of ATLG and ATG for Immune Reconstitution After Allo-HSCT for Hematologic Malignancy NCT06895538 | Peking University First Hospital | — |
| Recruiting | Eganelisib as Monotherapy and in Combination With Cytarabine in Relapsed/Refractory AML NCT06533761 | Stelexis BioSciences | Phase 1 |
| Recruiting | A Phase 1 Study of CG009301 for Injection in Adult Subjects With Recurrent or Refractory Haematological Malign NCT07347171 | Cullgen (Shanghai),Inc | Phase 1 |
| Recruiting | OURA Ring Wearable Testing in MDS Patients: a Feasibility and Discovery Pilot Study NCT06270771 | Sunnybrook Health Sciences Centre | — |
| Recruiting | BSB-1001 in Patients Undergoing HLA-Matched Allogenic Hematopoietic Stem Cell Transplant for AML, ALL or MDS NCT06704152 | BlueSphere Bio, Inc | Phase 1 / Phase 2 |
| Not Yet Recruiting | Selinexor Combined With Venetoclax Maintenance Therapy After Allo-HSCT NCT06765928 | Ruijin Hospital | Phase 2 |
| Enrolling By Invitation | A Multicenter Study on the Treatment of MDS/MPN Overlap Syndrome With AZA or Rux Combined With Selinexor NCT06664970 | Peking Union Medical College Hospital | Phase 2 |
| Not Yet Recruiting | A Study of HS-20106 to Treat Anemia Due to Very Low, Low, or Intermediate Risk Myelodysplastic Syndromes NCT06594965 | Hansoh BioMedical R&D Company | Phase 2 |
| Recruiting | CAR T-cell Therapy Directed to CD70 for Pediatric Patients With Hematological Malignancies NCT06326463 | St. Jude Children's Research Hospital | Phase 1 |
| Recruiting | Assessment of Measurable Residual Disease in Allo-HSCT Using Digital Polymerase Chain Reaction NCT06211166 | Peking University People's Hospital | — |
| Recruiting | Combination Salvage Therapy With Venetoclax and Decitabine in Relapsed/Refractory AML NCT06156579 | University Hospital Tuebingen | Phase 2 |
| Recruiting | High-Altitude Hematology Observation-Stem Cell Transplantation (HALO-SCT) NCT07205523 | Yigeng Cao,MD,PhD | — |
| Recruiting | A Pilot Study to Evaluate the Feasibility of Post-Hematopoietic Stem Cell Transplant Prophylaxis With Decitabi NCT05796570 | Franziska Wachter | Phase 2 |
| Unknown | To Evaluate the Phase I Clinical Study of XZB-0004 in Patients With AML and MDS NCT05740917 | Xuanzhu Biopharmaceutical Co., Ltd. | Phase 1 |
| Unknown | Clinical Efficacy and Mechanism of Yisui Granule in Treatment of Low and Medium Risk Myelodysplastic Syndrome NCT05687513 | Dongzhimen Hospital, Beijing | EARLY_Phase 1 |
| Recruiting | A Phase 1 Study With LYT-200 in Patients With Relapsed/Refractory Acute Myeloid Leukemia (AML), or With Relaps NCT05829226 | PureTech | Phase 1 |
| Active Not Recruiting | Venetoclax in Patients With MDS or AML in Relapse After AHSCT NCT05226455 | Groupe Francophone des Myelodysplasies | Phase 1 / Phase 2 |
| Recruiting | Tagraxofusp in Pediatric Patients With Relapsed or Refractory CD123 Expressing Hematologic Malignancies NCT05476770 | Therapeutic Advances in Childhood Leukemia Consortium | Phase 1 |
| Unknown | Venetoclax Plus RIC Regimen Allo-HSCT for Elderly Patients With High-risk Myeloid Malignancies NCT05583175 | Xianmin Song, MD | Phase 2 |
| Active Not Recruiting | Study Investigating Patient-Reported Outcomes in Lower-risk MDS Patients NCT05582902 | University of Leipzig | — |
| Recruiting | Study Evaluating Combination of Luspatercept in LR-MDS Without RS Having Failed or Being Ineligible to ESA NCT05181735 | Groupe Francophone des Myelodysplasies | Phase 1 / Phase 2 |
| Active Not Recruiting | A Phase II Study of Vibecotamab (XmAb14045) for MRD- Positive AML and MDS After Hypomethylating Agent Failure NCT05285813 | M.D. Anderson Cancer Center | Phase 2 |
| Active Not Recruiting | GvHD Prophylaxis in Unrelated Donor HCT: Randomized Trial Comparing PTCY Versus ATG NCT05153226 | DKMS gemeinnützige GmbH | Phase 3 |
| Active Not Recruiting | Fedratinib in Myelodysplastic /Myeloproliferative Neoplasms (MDS/MPNs) and Chronic Neutrophilic Leukemia (CNL) NCT05177211 | H. Lee Moffitt Cancer Center and Research Institute | Phase 2 |
| Completed | Safety and Efficacy of Allogeneic NK Cell Infusions in Patients With Relapsed/Refractory AML and High Risk MDS NCT04901416 | Coeptis Therapeutics | Phase 1 |
| Unknown | Phase 2, Open-Label, Single Arm Study, With BST-236 in Adults With R/R AML or Higher-Risk MDS NCT04749355 | BioSight Ltd. | Phase 2 |
| Unknown | Hetrombopag for Low/Intermediate-1 Risk MDS With Thrombocytopenia NCT05024877 | Peking Union Medical College Hospital | Phase 2 / Phase 3 |
| Terminated | APR-548 in Combination With Azacitidine for the Treatment of TP53 Myelodysplastic Syndromes (MDS) NCT04638309 | Aprea Therapeutics | Phase 1 |
| Recruiting | Optical Genome Mapping in Hematological Malignancies NCT05009537 | University Hospital, Brest | — |
| Recruiting | Precision Therapy Versus Standard Therapy in AML and MDS in Elderly NCT05025098 | University Hospital, Akershus | Phase 2 |
| Completed | ASTX727 and Donor Lymphocyte Infusions After Allogenic Stem Cell Transplantation in Very High Risk MDS or AML NCT04857645 | Groupe Francophone des Myelodysplasies | Phase 2 |
| Unknown | Aza With or Without ATRA in Newly Diagnosed Unfit AML or Intermediate,High or Very High Risk MDS NCT05175508 | The First Affiliated Hospital of Soochow University | Phase 2 / Phase 3 |
| Active Not Recruiting | A Study of CFI-400945 With or Without Azacitidine in Patients With AML, MDS or CMML NCT04730258 | Treadwell Therapeutics, Inc | Phase 1 / Phase 2 |
| Active Not Recruiting | Pilot Study of CC 486 (Oral Azacitidine) Plus BSC as Maintenance After sc Azacitidine in Elderly HR-IPSS-R MDS NCT04806906 | University of Florence | Phase 2 |
| Unknown | Prognostic Value of Serum Erythropoietin Level,Ferritin Level and Fibrinogen in Adult Low Risk MDS NCT04573686 | Assiut University | — |
| Unknown | A Study of APG-115 Alone or Combined With Azacitidine in Patients With AML, CMML, or MDS NCT04358393 | Ascentage Pharma Group Inc. | Phase 1 / Phase 2 |
| Recruiting | National Longitudinal Cohort of Hematological Diseases NCT04645199 | Institute of Hematology & Blood Diseases Hospital, China | — |
| Recruiting | Cord Blood Transplant in Children and Young Adults With Blood Cancers and Non-malignant Disorders NCT04644016 | Memorial Sloan Kettering Cancer Center | Phase 2 |
| Active Not Recruiting | NKX101, Intravenous Allogeneic CAR NK Cells, in Adults With AML or MDS NCT04623944 | Nkarta, Inc. | Phase 1 |
| Completed | A Safety and Efficacy Study of SHR-1702 Monotherapy in Patients With Acute Myeloid Leukemia (AML) or Myelodysp NCT04443751 | Jiangsu HengRui Medicine Co., Ltd. | Phase 1 |
| Active Not Recruiting | A Study Comparing Haploidentical Hematopoietic Stem Cell Transplantations (HSCTs) From Young Non-first-degree NCT04547049 | First Affiliated Hospital of Zhejiang University | Phase 3 |
| Suspended | A Study Evaluating the Safety and Efficacy of IBI188 in Combination With AZA in Subjects With Newly Diagnosed NCT04511975 | Innovent Biologics (Suzhou) Co. Ltd. | Phase 1 |
| Completed | Haplo Peripheral Blood Sct In GVHD Prevention NCT04473911 | Zachariah Michael DeFilipp | Phase 1 |
| Recruiting | BMT-06: Study of Intensity Modulated Total Marrow Irradiation (IM-TMI) NCT04187105 | University of Illinois at Chicago | Phase 2 |
| Active Not Recruiting | Efficacy and Safety of HMAs Combined With Venetoclax Versus HMAs Alone in ND Int-and H-risk MDS or CMML NCT07318662 | Guangdong Provincial People's Hospital | — |
| Withdrawn | CPX-351 in Patients Treated for Higher-risk Myelodysplastic Syndromes Experiencing Hypomethylating Agent Failu NCT04109690 | Yale University | Phase 1 / Phase 2 |
| Unknown | Mutational Analysis as a Prognostic and Predictive Marker of Cardiovascular (CVD) Disease in Patients With Mye NCT04110925 | Sunnybrook Health Sciences Centre | N/A |
| Recruiting | Comparison of Therapies Before Stem Cell Transplantation in Patients With Higher Risk MDS and Oligoblastic AML NCT04061239 | GWT-TUD GmbH | Phase 2 |
| Completed | CYC065 CDK Inhibitor and Venetoclax Study in Relapsed/Refractory AML or MDS NCT04017546 | Cyclacel Pharmaceuticals, Inc. | Phase 1 |
| Unknown | Study on High-risk MDS Patients Based on RNA-seq Technology NCT03903055 | Zhejiang Provincial Hospital of TCM | — |
| Completed | APR-246 & Azacitidine for the Treatment of TP53 Mutant Myelodysplastic Syndromes (MDS) NCT03745716 | Aprea Therapeutics | Phase 3 |
| Unknown | Chidamide Plus PTCy/Cyclosporine to Prevent GVHD After Myeloablative Conditioning, Matched PBSCT NCT03336632 | Sichuan University | Phase 2 |
| Unknown | Study of APVO436 in Patients With AML or MDS NCT03647800 | Aptevo Research and Development LLC | Phase 1 |
| Recruiting | Frailty Phenotype Assessments to Optimize Treatment Strategies for Older Patients With Hematologic Malignancie NCT03680677 | Abramson Cancer Center at Penn Medicine | — |
| Completed | DEPLETHINK - LymphoDEPLEtion and THerapeutic Immunotherapy With NKR-2 NCT03466320 | Celyad Oncology SA | Phase 1 / Phase 2 |
| Terminated | Safety, Tolerability, Pharmacokinetics and Efficacy of AMG 397 in Subjects With Selected Relapsed or Refractor NCT03465540 | Amgen | Phase 1 |
| Completed | Pevonedistat and Low Dose Cytarabine in Adult Patients With AML and MDS NCT03459859 | Justin Watts, MD | Phase 1 |
| Unknown | Mutant p53-based Personalized Trial Using Decitabine and Arsenic Trioxide on AML/MDS NCT03855371 | Ruijin Hospital | Phase 1 |
| Completed | Haploidentical Donor vs mMUD in Hematological Malignancies NCT03275636 | DKMS gemeinnützige GmbH | Phase 2 / Phase 3 |
| Completed | Ascorbic Acid Levels in MDS, AML, and CMML Patients NCT03526666 | Van Andel Research Institute | — |
| Withdrawn | iCare3: Monitoring Circulating Cancer DNA After Chemotherapy in MDS and AML NCT03138395 | University of Florida | — |
| Completed | CX-01 Combined With Azacitidine in the Treatment of Relapsed or Refractory Myelodysplastic Syndrome and Acute NCT02995655 | Washington University School of Medicine | Phase 1 |
| Recruiting | Familial Investigations of Childhood Cancer Predisposition NCT03050268 | St. Jude Children's Research Hospital | — |
| Completed | A Study of Azacitidine in Myelodysplastic Syndrome (MDS) Associated to Systemic Auto-immune and Inflammatory D NCT02985190 | Groupe Francophone des Myelodysplasies | Phase 2 |
| Unknown | Individual Molecular MRD Monitoring for MDS Patients After Allo-SCT NCT02872662 | Nordic MDS Group | — |
| Completed | Allogeneic Hematopoietic Stem Cell Transplantation in Patients With Myelodysplastic Syndrome Low Risk NCT02757989 | Groupe Francophone des Myelodysplasies | N/A |
| Terminated | Controlled Study of Rigosertib Versus Physician's Choice of Treatment in MDS Patients After Failure of an HMA NCT02562443 | Traws Pharma, Inc. | Phase 3 |
| Terminated | A Study of E6201 for the Treatment of Advanced Hematologic Malignancies With FLT3 and/or Ras Mutations NCT02418000 | Spirita Oncology, LLC | Phase 1 / Phase 2 |
| Completed | Nonmyeloablative Hematopoietic Cell Transplantation (HCT) for Patients With Hematologic Malignancies Using Rel NCT02167958 | Rafic Farah, MD | Phase 1 |
| Completed | A Study of LDE255 in Combination With Azacitidine for High Risk Myelodysplastic Syndrome Patients NCT02323139 | Groupe Francophone des Myelodysplasies | Phase 1 |
| Completed | Pharmacokinetic Guided Dose Escalation and Dose Confirmation With Oral Decitabine and Oral Cytidine Deaminase NCT02103478 | Astex Pharmaceuticals, Inc. | Phase 1 / Phase 2 |
| Completed | Randomized Phase III Study of Decitabine +/- Hydroxyurea (HY) Versus HY in Advanced Proliferative CMML NCT02214407 | Groupe Francophone des Myelodysplasies | Phase 3 |
| Completed | Ultra-Low Dose IL-2 Therapy as GVHD Prophylaxis in Haploidentical Allogeneic Stem Cell Transplantation NCT02226861 | National Heart, Lung, and Blood Institute (NHLBI) | Phase 1 |
| Completed | A Phase II Trial of SGI-110 in Patients With IPSS High and Int 2 Myelodysplastic Syndrome, Acute Myeloid Leuke NCT02197676 | Groupe Francophone des Myelodysplasies | Phase 2 |
| Completed | Study of FF-10501-01 in Patients With Relapsed or Refractory Hematological Malignancies NCT02193958 | Fujifilm Pharmaceuticals U.S.A., Inc. | Phase 1 / Phase 2 |
| Completed | Allo vs Hypomethylating/Best Supportive Care in MDS (BMTCTN1102) NCT02016781 | Medical College of Wisconsin | Phase 2 |
| Withdrawn | Haplo-identical SCT for High Risk (HR) Hematologic Malignancies w/Post-Transplant In-Vivo T-cell Depletion NCT02053545 | Ann & Robert H Lurie Children's Hospital of Chicago | Phase 1 / Phase 2 |
| Completed | Phase 2 Study Adding Pracinostat to a Hypomethylating Agent (HMA) in Patients With MDS Who Failed to Respond t NCT01993641 | Helsinn Healthcare SA | Phase 2 |
| Recruiting | Allogeneic Hematopoietic Stem Cell Transplant for GATA2 Mutations NCT01861106 | National Cancer Institute (NCI) | Phase 2 |
| Unknown | A Study of Combined Deferasirox, Vitamin D and Azacytidine in High Risk MDS NCT01718366 | Groupe Francophone des Myelodysplasies | Phase 1 / Phase 2 |
| Completed | Decitabine Combining Modified CAG Followed by HLA Haploidentical Peripheral Blood Mononuclear Cells Infusion f NCT01690507 | Chinese PLA General Hospital | Phase 1 / Phase 2 |
| Terminated | FLT-PET Imaging for MDS NCT01535456 | University of Wisconsin, Madison | N/A |
| Completed | Efficacy and Safety of Oral Rigosertib in Transfusion-dependent, Low or Int-1 or Trisomy 8 Int-2 Myelodysplast NCT01584531 | Traws Pharma, Inc. | Phase 2 |
| Completed | Darbepoetin Alfa in Patients With Anemic Low or Intermediate-1 Risk Myelodysplastic Syndrome (MDS) NCT01362140 | Amgen | Phase 3 |
| Completed | A Clinical Study of KRN321 in Adult Subjects With Myelodysplastic Syndrome NCT01497145 | Kyowa Kirin Co., Ltd. | Phase 2 |
| Completed | The Effect of Blood Transfusion on Endothelial Function NCT02161042 | London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's | — |
| Unknown | ClAraC or FLAMSA Followed by Stem Cell Transplantation to Treat High Risk AML or Advanced MDS NCT01423175 | Hannover Medical School | Phase 2 |
| Unknown | Best Promising Drug Association With Azacitidine in Higher Risk Myelodysplastic Syndromes NCT01342692 | Assistance Publique - Hôpitaux de Paris | Phase 2 |
| Completed | SGI-110 in Participants With Myelodysplastic Syndromes (MDS) or Acute Myelogenous Leukemia (AML) NCT01261312 | Astex Pharmaceuticals, Inc. | Phase 1 / Phase 2 |
| Terminated | A Trial of Lenalidomide & Azacitidine in Low Risk Myelodysplastic Syndromes NCT01379274 | Rush University Medical Center | Phase 2 |
| Completed | Randomized Study of ON 01910.Na in Refractory Myelodysplastic Syndrome Patients With Excess Blasts NCT01241500 | Traws Pharma, Inc. | Phase 3 |
| Completed | Phase 1 Study of TG02 Citrate in Patients With Advanced Hematological Malignancies NCT01204164 | Tragara Pharmaceuticals, Inc. | Phase 1 |
| Completed | Non-interventional Study With Azacitidin (Vidaza®) NCT01192945 | iOMEDICO AG | — |
| Completed | Lenalidomide and Prednisone in Low and Int-1 Myelodysplastic Syndrome (MDS) Non 5q MDS NCT01133275 | H. Lee Moffitt Cancer Center and Research Institute | Phase 2 |
| Completed | Non Interventional Study on Iron Toxicity After First Allo-transplant in MDS/CMML NCT06267898 | European Society for Blood and Marrow Transplantation | — |
| Completed | Fludarabine and Cytarabine in Acute Myelogenous Leukemia (AML) and High-Risk Myelodysplastic Syndrome (MDS) NCT01019317 | M.D. Anderson Cancer Center | Phase 2 |
| Completed | Allogeneic Stem Cell Transplant With Clofarabine, Busulfan and Antithymocyte Globulin (ATG) for Adult Patients NCT00863148 | Nantes University Hospital | Phase 2 |
| Terminated | Pilot Trial of Targeted Immune-Depleting Chemotherapy and Reduced-Intensity Matched Unrelated Double Cord Bloo NCT00973804 | National Cancer Institute (NCI) | Phase 1 |
| Completed | Pilot and Feasibility Study of Reduced-Intensity Hematopoietic Stem Cell Transplant for MonoMAC NCT00923364 | National Cancer Institute (NCI) | Phase 2 |
| Completed | Controlled Study of Post-transplant Azacitidine for Prevention of Acute Myelogenous Leukemia and Myelodysplast NCT00887068 | M.D. Anderson Cancer Center | Phase 3 |
| Completed | STA-9090 for Treatment of AML, CML, MDS and Myeloproliferative Disorders NCT00858572 | Synta Pharmaceuticals Corp. | Phase 1 |
| Recruiting | Global Registry and Natural History Study for Mitochondrial Disorders NCT05554835 | LMU Klinikum | — |
| Completed | Umbilical Cord Blood Transplant for Hematological Malignancies NCT00891592 | University of Pennsylvania | Phase 1 |
| Completed | Safety Study of Bone Marrow Transplant Using Mismatched Tissue Followed by Chemotherapy NCT00796562 | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | Phase 2 |
| Completed | Pharmacokinetics and Safety Study of Azacitidine in Cancer Patients With and Without Impaired Renal Function NCT00652626 | Celgene | Phase 1 |
| Unknown | Feasibility and Efficacy Study of Conditioning Regimen for Allogeneic Hematopoietic Cell Transplantation (HCT) NCT00815568 | Samsung Medical Center | Phase 2 |
| Completed | Romiplostim Treatment of Thrombocytopenia in Subjects With Low or Intermediate-1 Risk Myelodysplastic Syndrome NCT00614523 | Amgen | Phase 2 |
| Terminated | A Dose Range Finding Study of Lenalidomide in Non-5q Chromosome Deletion in Low and Intermediate Risk Myelodys NCT00699842 | Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University | Phase 1 / Phase 2 |
| Completed | Evaluation of Formin Gene Status and Expression in Myeloproliferative and Myelodysplastic Disorders NCT00687414 | Corewell Health West | — |
| Completed | Safety Study of IL-7 in Recipients of a Hemopoietic Stem Cell Transplant Peripheral Blood Stem Cell Transplant NCT00684008 | Cytheris, Inc. | Phase 1 |
| Completed | Lenalidomide in High-risk MDS and AML With Del(5q) or Monosomy 5 NCT00761449 | Nordic MDS Group | Phase 2 |
| Completed | Phase I Study of Gimatecan in Patients With Myelodysplastic Syndromes NCT00493571 | M.D. Anderson Cancer Center | Phase 1 |
| Terminated | Myeloablative Allogeneic Stem Cell Transplantation Using a Naive T-Cell Depleted Peripheral Blood Stem Cell Gr NCT00814983 | Duke University | Phase 1 / Phase 2 |
| Completed | Evaluating the Safety of Long Term Dosing of Romiplostim (Formerly AMG 531) in Thrombocytopenic Subjects With NCT00472290 | Amgen | N/A |
| Completed | A Phase I Study of AC220 in Patients With Relapsed/Refractory Acute Myeloid Leukemia Regardless of FLT3 Status NCT00462761 | Daiichi Sankyo | Phase 1 |
| Completed | Determination of Safe and Effective Dose of Romiplostim (AMG 531) in Subjects With Myelodysplastic Syndrome (M NCT00321711 | Amgen | Phase 2 |
| Terminated | Velcade in Myelodysplastic Syndrome - Pilot Study NCT00440076 | Gruppo Italiano Malattie EMatologiche dell'Adulto | Phase 2 |
| Completed | Determination of Safe Dose of Romiplostim (AMG 531) in Patients With Myelodysplastic Syndromes (MDS) NCT00303472 | Amgen | Phase 2 |
| Completed | Unrelated Umbilical Cord Blood Transplantation Augmented With ALDHbr Umbilical Cord Blood Cells NCT00692926 | Joanne Kurtzberg, MD | Phase 1 |
| Completed | Myeloablative Umbilical Cord Blood Transplantation in Hematological Diseases NCT00309842 | Masonic Cancer Center, University of Minnesota | Phase 2 |
| Terminated | Stem Cell Transplant for Hematological Malignancy NCT00176930 | Masonic Cancer Center, University of Minnesota | N/A |
| Completed | Allogeneic Transplantation From Related Haploidentical Donors NCT00185692 | Stanford University | Phase 2 |
| Terminated | Stem Cell Transplantation for Hematological Malignancies NCT00176839 | Masonic Cancer Center, University of Minnesota | Phase 2 / Phase 3 |
| Completed | Nonmyeloablative Allo SCT for the Treatment of Hematologic Disorders NCT00636909 | Beth Israel Deaconess Medical Center | Phase 2 |
| Completed | Ganciclovir by Infusion and by Mouth in Treating Patients With Cytomegalovirus After Donor Bone Marrow Transpl NCT00530218 | City of Hope Medical Center | Phase 2 |
| Completed | Donor Lymphocyte Infusion (DLI) for Relapsed (Post Transplant) Leukemia NCT00167167 | Masonic Cancer Center, University of Minnesota | N/A |